Traditional recipes

Flu Shots Are Safe for People With Egg Allergies, New Report Shows

Flu Shots Are Safe for People With Egg Allergies, New Report Shows


We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

Egg allergic patients don’t need a special flu shot, after all

istockphoto.com

The vaccine is not dangerous for those with the allergy, a new study shows.

People with egg allergies have historically stayed away from the flu vaccine. However, a paper published on December 19 suggests that these anxieties over the egg-based shot were for naught. The flu shot was deemed safe, even for those with egg allergies.

“People with egg allergy of any severity can receive the influenza vaccine without any special precautions,” Dr. Matthew Greenhawt, the paper’s lead author, told CNN.

Experts hope that this new revelation with encourage more people to get their flu shot without caution. No flu vaccine is ever 100 percent effective — last year’s vaccine was just 42 percent effective. But that doesn’t mean you shouldn’t get one. The flu vaccine is a method of prevention recommended by almost every doctor and health specialist, including those at the Centers of Disease Control and Prevention. Even still, only 46.8 percent of people in the United States received a vaccination for last year’s flu season.

Not that very many people are avoiding the shot solely due to an egg allergy — just two percent of all children experience an egg allergy and it’s rare that these allergies last through adulthood.

“One redeeming quality about egg allergy is that the majority of it is outgrown at some point in childhood, with a very small proportion of individuals retaining that into adulthood,” explained Greenhawt.

Now there’s one less excuse for avoiding your flu shot this season — it’s time to go get yours. Before you go, brush up on these 15 things you need to know before you get vaccinated.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.



Comments:

  1. Keramar

    Where can I find this?

  2. Donny

    Something like that does not appear

  3. Faer

    Curious, but it's not clear

  4. Windgate

    I think this - confusion.

  5. Pentheus

    Bravo, you visited another idea

  6. Dashicage

    I think you will allow the mistake. Enter we'll discuss it. Write to me in PM.

  7. Ulises

    And how in that case it is necessary to act?



Write a message